Nathan Ihle

Nathan Ihle has extensive experience in the field of oncology. Nathan is currently working as the Executive Director of Cancer Biology at Zai Lab. Prior to this, they held the position of Senior Director of Oncology at XinThera, Inc. from 2021 to 2023. Nathan had a long tenure at Pfizer, where they served as a Senior Principal Scientist from 2018 to 2021 and as a Principal Scientist from 2013 to 2018. Nathan played a key role in leading project teams in the development of oncology agents and assessing exploratory targets for development potential.

Before joining Pfizer, Nathan worked at MD Anderson Cancer Center, where they held various roles. Nathan worked as a Graduate Research Assistant from 2010 to 2012, focusing on the KRas oncogene and collaborating with statisticians and clinicians on lung cancer trial results. As a Program Coordinator from 2005 to 2010, they led the research program for PX-866, an irreversible pan-PI3K inhibitor. Nathan also proposed and published risk mitigation strategies and patient selection strategies, resulting in publications and a patent.

Nathan began their career as a Research Technician/Specialist at The University of Arizona Health Sciences, where they designed and conducted experiments related to PI3K and Akt signaling inhibitors. Nathan managed and maintained laboratory resources during their tenure from 2001 to 2005. Overall, Nathan Ihle's work experience demonstrates a strong background in oncology research, project leadership, and scientific publications.

Nathan Ihle holds a Bachelor's Degree in Environmental Sciences from the University of Arizona, which they obtained between 1996 and 2001. In 2010, Ihle pursued a Doctor of Philosophy (Ph.D.) degree in Experimental Therapeutics from The University of Texas Health Science Center at Houston (UTHealth Houston), completing it in 2012.